Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $1.48 up 4.23% from its previous closing price of $1.42. In other words, the price has increased by $4.23 from its previous closing price. On the day, 2.23 million shares were traded. ALLO stock price reached its highest trading level at $1.5 during the session, while it also had its lowest trading level at $1.41.
Ratios:
For a deeper understanding of Allogene Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.19 and its Current Ratio is at 8.19. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.24.
Citizens JMP Upgraded its Mkt Perform to Mkt Outperform on March 14, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’25 when Beneski Benjamin Machinas sold 786 shares for $1.22 per share. The transaction valued at 959 led to the insider holds 217,721 shares of the business.
Beneski Benjamin Machinas bought 786 shares of ALLO for $959 on Nov 17 ’25. On Oct 21 ’25, another insider, Parker Geoffrey M., who serves as the CHIEF FINANCIAL OFFICER of the company, sold 36,744 shares for $1.26 each. As a result, the insider received 46,169 and left with 1,276,796 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 332600608 and an Enterprise Value of 165548608.
Stock Price History:
The Beta on a monthly basis for ALLO is 0.51, which has changed by -0.29702967 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is 14.87%, while the 200-Day Moving Average is calculated to be 10.97%.
Shares Statistics:
For the past three months, ALLO has traded an average of 2.73M shares per day and 2368790 over the past ten days. A total of 223.16M shares are outstanding, with a floating share count of 159.44M. Insiders hold about 29.05% of the company’s shares, while institutions hold 50.56% stake in the company. Shares short for ALLO as of 1764288000 were 18663734 with a Short Ratio of 6.85, compared to 1761868800 on 19094028. Therefore, it implies a Short% of Shares Outstanding of 18663734 and a Short% of Float of 10.0.
Earnings Estimates
Allogene Therapeutics Inc (ALLO) is currently under the scrutiny of 10.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.18 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.74 and -$1.2 for the fiscal current year, implying an average EPS of -$0.94. EPS for the following year is -$0.91, with 10.0 analysts recommending between -$0.43 and -$1.47.
